Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2023. For the fiscal year ending, the company expected to report revenue of JPY 24,000 million and operating profit of JPY 5,260 million. the expected profit attributable to owners of parent is JPY 7,000 million and profit per share is JPY 168.13.
Shin Nippon Biomedical Laboratories, Ltd.
Equities
2395
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,502 JPY | +1.49% | +5.55% | -11.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.54% | 397M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- 2395 Stock
- News Shin Nippon Biomedical Laboratories, Ltd.
- Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023